Impel Pharmaceuticals
(OTC) IMPL
Impel Pharmaceuticals Financials at a Glance
Market Cap
N/A
Revenue (TTM)
$20.99M
Net Income (TTM)
$96.11M
EPS (TTM)
N/A
P/E Ratio
N/A
Dividend
N/A
Beta (Volatility)
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
Dividend
N/A
Beta (Volatility)
N/A
Price
N/A
Volume
N/A
Open
N/A
Previous Close
N/A
Daily Range
N/A
52-Week Range
N/A
IMPL News
IMPL: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Impel Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
160
CEO
Adrian Adams
Website
www.impelnp.comHeadquarters
Seattle, WA 98119, US
IMPL Financials
Key Financial Metrics (TTM)
Gross Margin
49%
Operating Margin
-7%
Net Income Margin
-10%
Return on Equity
-31%
Return on Capital
-1%
Return on Assets
-1%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
N/A
Shares Outstanding
N/A
Volume
N/A
Short Interest
N/A
Avg. Volume
N/A
Financials (TTM)
Gross Profit
$6.16M
Operating Income
$83.18M
EBITDA
$91.28M
Operating Cash Flow
$93.64M
Capital Expenditure
$1.38M
Free Cash Flow
$95.02M
Cash & ST Invst.
$60.65M
Total Debt
$51.19M
Impel Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$5.02M
+63.0%
Gross Profit
$2.79M
+77.4%
Gross Margin
55.60%
N/A
Market Cap
N/A
N/A
Market Cap/Employee
N/A
N/A
Employees
160
N/A
Net Income
$13.81M
+66.3%
EBITDA
$16.84M
+50.5%
Quarterly Fundamentals
Net Cash
$114.56M
-489.1%
Accounts Receivable
$6.59M
+7.6%
Inventory
$6.86M
-20.4%
Long Term Debt
$2.23M
-95.4%
Short Term Debt
$112.56M
+8262.8%
Return on Assets
-1.46%
N/A
Return on Invested Capital
-1.25%
N/A
Free Cash Flow
$17.48M
+23.4%
Operating Cash Flow
$16.52M
+27.1%